MedTrace Logo

A Study of DZD2269 in Healthy Adult Participants

NCT04932005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-07-01

No results posted yet for this study

Summary

This is a research study in healthy participants. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. This study will also investigate pharmacokinetics of DZD2269; renal excretion of DZD2269 will also be evaluated. The study will also measure biomarkers such as pCREB in the blood.

Conditions

  • Healthy Volunteers

Interventions

DRUG

DZD2269

Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.

DRUG

placebo

Part A: A single oral dose. Part C: Twice daily dosing for 7 days.

Sponsors & Collaborators

  • Dizal Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Frank Lee, MD · Frontage Clinical Services, Inc.

  • Lisa Diamond, PhD · Frontage Clinical Services, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2022-04-01
Completion
2022-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932005 on ClinicalTrials.gov